Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Maltais, J. Ostinelli, J. Bourbeau, A. Tonnel, N. Jacquemet, J. Haddon, M. Rouleau, M. Boukhana, J. Martinot, P. Duroux (2002)
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.American journal of respiratory and critical care medicine, 165 5
W. Thompson, C. Nielson, P. Carvalho, N. Charan, J. Crowley (1996)
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.American journal of respiratory and critical care medicine, 154 2 Pt 1
D. Niewoehner, M. Erbland, Deupree Rh, D. Collins, N. Gross, R. Light, P. Anderson, N. Morgan (1999)
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.The New England journal of medicine, 340 25
D. O’Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D. Marciniuk, M. Balter, G. Ford, A. Gervais, R. Goldstein, R. Hodder, A. Kaplan, S. Keenan, Y. Lacasse, F. Maltais, J. Road, G. Rocker, D. Sin, T. Sinuff, N. Voduc (2007)
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.Canadian respiratory journal, 14 Suppl B
L Davies, RM Angus, PM Calverley (1999)
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial., 354
JA Wedzicha (2000)
Oral corticosteroids for exacerbations of chronic obstructive pulmonary diseaseThorax, 55
JD Leuppi, P Schuetz, R Bingisser (2013)
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial [published online May 21, 2013]., 309
S. Aaron, K. Vandemheen, P. Hebert, R. Dales, I. Stiell, J. Ahuja, G. Dickinson, R. Brison, B. Rowe, J. Dreyer, E. Yetisir, D. Cass, G. Wells (2003)
Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.The New England journal of medicine, 348 26
J. Leuppi, P. Schuetz, R. Bingisser, M. Bodmer, M. Briel, T. Drescher, Ursula Duerring, C. Henzen, Yolanda Leibbrandt, Sabrina Maier, D. Miedinger, B. Müller, A. Scherr, C. Schindler, R. Stoeckli, S. Viatte, C. Garnier, M. Tamm, J. Rutishauser (2013)
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.JAMA, 309 21
(2011)
Centers for Disease Control and Prevention. National vital statistics reports: deaths: preliminary data
Shawn Aaron, K. Vandemheen, F. Maltais, Stephen Field, Don Sin, J. Bourbeau, D. Marciniuk, J. Fitzgerald, Parameswaran Nair, R. Mallick (2012)
TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trialThorax, 68
A. Sayıner, Z. Aytemur, M. Cirit, İpek Ünsal (2001)
Systemic glucocorticoids in severe exacerbations of COPD.Chest, 119 3
A. Adelman (1999)
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.The Journal of family practice, 48 10
J. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Müllerová, R. Tal-Singer, B. Miller, D. Lomas, A. Agustí, W. Macnee, P. Calverley, S. Rennard, E. Wouters, J. Wedzicha (2010)
Susceptibility to exacerbation in chronic obstructive pulmonary disease.The New England journal of medicine, 363 12
D Hoyert, J Xu
National vital statistics reports: deaths: preliminary data for 2011, vol 61, no 6.
K. Rabe, S. Hurd, A. Anzueto, P. Barnes, Sonia Buist, P. Calverley, Yoshinosuke Fukuchi, C. Jenkins, R. Rodríguez-Roisín, C. Weel, Jan Zieliński (2007)
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.American journal of respiratory and critical care medicine, 176 6
(2010)
Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease
Editorials represent the opinions EDITORIAL of the authors and JAMA and not those of the American Medical Association. ONLINE FIRST Less Is Clearly More 2,10 (approximately40 mg/d). However, even using this con- Don D. Sin, MD servative regimen, patients frequently experience adverse Hye Yun Park, MD, PhD effects of corticosteroids including hyperglycemia, weight gain, and insomnia. Moreover, because approximately 10% HRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) of patients experience frequent exacerbations (defined as 2 is a common, progressive lung condition, char- or more exacerbations annually), cumulative exposure to acterized by cough and dyspnea and punctuated oral corticosteroids may be substantial in some patients, lead- Cby episodes of acute exacerbations or “lung at- ing to serious long-term steroid toxicity, including weight tacks” during which these symptoms significantly in- gain, diabetes, osteoporosis, fractures, adrenal suppres- crease. These lung attacks can induce severe symptoms, caus- sion, and ocular complications. Because steroid toxicity is ing patients to seek urgent medical care and can result in dose and duration dependent, ascertainment of a minimal respiratory failure and death. In the United States, COPD effective dose to treat acute exacerbations is of critical clini- exacerbations are responsible for more than 800 000 hos- cal importance for
JAMA – American Medical Association
Published: Jun 5, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.